254 related articles for article (PubMed ID: 33044355)
1. Polaprezinc (Zinc-L-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions: A Pilot Study.
Sakae K; Suka M; Yanagisawa H
J Clin Psychopharmacol; 2020; 40(6):599-606. PubMed ID: 33044355
[TBL] [Abstract][Full Text] [Related]
2. Oral treatment of pressure ulcers with polaprezinc (zinc L-carnosine complex): 8-week open-label trial.
Sakae K; Yanagisawa H
Biol Trace Elem Res; 2014 Jun; 158(3):280-8. PubMed ID: 24691900
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data.
Furihata K; Tsuchikawa M; Miwa T; Naito Y; Oba K; Sakagami M
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32316581
[TBL] [Abstract][Full Text] [Related]
4. Zinc-L-Carnosine Complex (Polaprezinc) for the Treatment of Binge Eating: Three Case Reports.
Sakae K; Yanagisawa H
J Clin Psychopharmacol; 2017 Dec; 37(6):734-736. PubMed ID: 28926352
[No Abstract] [Full Text] [Related]
5. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
Dalai SS; Adler S; Najarian T; Safer DL
Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
[TBL] [Abstract][Full Text] [Related]
6. [Triggers of bulimia and compulsion attacks: validation of the "Start" questionnaire].
Rigaud D; Jiang T; Pennacchio H; Brémont M; Perrin D
Encephale; 2014 Sep; 40(4):323-9. PubMed ID: 24091068
[TBL] [Abstract][Full Text] [Related]
7. Different moderators of cognitive-behavioral therapy on subjective and objective binge eating in bulimia nervosa and binge eating disorder: a three-year follow-up study.
Castellini G; Mannucci E; Lo Sauro C; Benni L; Lazzeretti L; Ravaldi C; Rotella CM; Faravelli C; Ricca V
Psychother Psychosom; 2012; 81(1):11-20. PubMed ID: 22116257
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis.
Itagaki M; Saruta M; Saijo H; Mitobe J; Arihiro S; Matsuoka M; Kato T; Ikegami M; Tajiri H
Scand J Gastroenterol; 2014 Feb; 49(2):164-72. PubMed ID: 24286534
[TBL] [Abstract][Full Text] [Related]
9. Bulimia nervosa-nonpurging subtype: closer to the bulimia nervosa-purging subtype or to binge eating disorder?
Jordan J; McIntosh VV; Carter JD; Rowe S; Taylor K; Frampton CM; McKenzie JM; Latner J; Joyce PR
Int J Eat Disord; 2014 Apr; 47(3):231-8. PubMed ID: 24282157
[TBL] [Abstract][Full Text] [Related]
10. Residence time of polaprezinc (zinc L-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites.
Furuta S; Toyama S; Miwa M; Itabashi T; Sano H; Yoneta T
Jpn J Pharmacol; 1995 Apr; 67(4):271-8. PubMed ID: 7650862
[TBL] [Abstract][Full Text] [Related]
11. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
12. Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
Fukushima T; Horike H; Fujiki S; Kitada S; Sasaki T; Kashihara N
Ther Apher Dial; 2009 Jun; 13(3):213-9. PubMed ID: 19527468
[TBL] [Abstract][Full Text] [Related]
13. Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats.
Kono T; Asama T; Chisato N; Ebisawa Y; Okayama T; Imai K; Karasaki H; Furukawa H; Yoneda M
Life Sci; 2012 Jan; 90(3-4):122-30. PubMed ID: 22100444
[TBL] [Abstract][Full Text] [Related]
14. Smoking status and psychosocial factors in binge eating disorder and bulimia nervosa.
Chao AM; White MA; Grilo CM
Eat Behav; 2016 Apr; 21():54-8. PubMed ID: 26741260
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL; Adler S; Dalai SS; Bentley JP; Toyama H; Pajarito S; Najarian T
Int J Eat Disord; 2020 Feb; 53(2):266-277. PubMed ID: 31721257
[TBL] [Abstract][Full Text] [Related]
16. A pilot study examining diagnostic differences among exercise and weight suppression in bulimia nervosa and binge eating disorder.
Cook BJ; Steffen KJ; Mitchell JE; Otto M; Crosby RD; Cao L; Wonderlich SA; Crow S; Hill L; Le Grange D; Powers P
Eur Eat Disord Rev; 2015 May; 23(3):241-5. PubMed ID: 25754428
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacotherapy options for bulimia nervosa and binge eating disorder.
McElroy SL; Guerdjikova AI; Mori N; O'Melia AM
Expert Opin Pharmacother; 2012 Oct; 13(14):2015-26. PubMed ID: 22946772
[TBL] [Abstract][Full Text] [Related]
18. Effects of polaprezinc on morphological change of the tongue in zinc-deficient rats.
Kinomoto T; Sawada M; Ohnishi Y; Yamaguchi T; Tsuge S; Ogawa S; Washizuka M; Minaguchi J; Mera Y; Takehana K
J Oral Pathol Med; 2010 Sep; 39(8):617-23. PubMed ID: 21054547
[TBL] [Abstract][Full Text] [Related]
19. Effect of polaprezinc on taste disorders in zinc-deficient rats.
Hamano H; Yoshinaga K; Eta R; Emori Y; Kawasaki D; Iino Y; Sawada M; Kuroda H; Takei M
Biofactors; 2006; 28(3-4):185-93. PubMed ID: 17473379
[TBL] [Abstract][Full Text] [Related]
20. Dietary Restriction Behaviors and Binge Eating in Anorexia Nervosa, Bulimia Nervosa and Binge Eating Disorder: Trans-diagnostic Examination of the Restraint Model.
Elran-Barak R; Sztainer M; Goldschmidt AB; Crow SJ; Peterson CB; Hill LL; Crosby RD; Powers P; Mitchell JE; Le Grange D
Eat Behav; 2015 Aug; 18():192-6. PubMed ID: 26122390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
